Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Update

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 7,100 shares, a growth of 121.9% from the March 31st total of 3,200 shares. Based on an average trading volume of 7,300 shares, the short-interest ratio is presently 1.0 days.

Calliditas Therapeutics AB (publ) Trading Up 0.3 %

NASDAQ CALT traded up $0.05 during trading on Friday, reaching $19.50. 3,791 shares of the company’s stock traded hands, compared to its average volume of 5,589. Calliditas Therapeutics AB has a 12-month low of $15.25 and a 12-month high of $29.30. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89. The company’s 50 day simple moving average is $20.86 and its two-hundred day simple moving average is $20.63.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last issued its quarterly earnings data on Wednesday, February 21st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02. The company had revenue of $42.45 million for the quarter, compared to analyst estimates of $36.24 million. Calliditas Therapeutics AB (publ) had a negative net margin of 38.72% and a negative return on equity of 104.47%. During the same period last year, the company posted ($0.01) earnings per share. Research analysts anticipate that Calliditas Therapeutics AB will post 0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Calliditas Therapeutics AB (publ) in a report on Thursday, February 22nd.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

An institutional investor recently bought a new position in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new position in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 980 shares of the company’s stock, valued at approximately $25,000. 2.83% of the stock is currently owned by institutional investors.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.